Two women smiling

Ready to write your
first Qlosi prescription?

Here’s everything you need
to get your patients started

How to prescribe Qlosi1

Identify the right patient: adults with symptomatic presbyopia seeking a reader-free option, including emerging presbyopes, established presbyopes, pseudophakes, and contact lens wearers
Perform a full fundus exam before initiating Qlosi,
as with all miotics
Prescribe Qlosi (pilocarpine ophthalmic solution) 0.4%, available in 30-vial and 60-vial packs
Set expectations with the Clear Start Week: 2 doses daily
for 7 days to establish neuroadaptation
Qlosi carton with foil pouches and vials

Not actual size

Send to BlinkRx pharmacy Delivered directly to the patient’s door in 5–7 days
Follow up 2–3 weeks later to assess clear near vision and patient satisfaction

Who’s the right patient?

Dr. Brian Brightman
The slam dunk candidate for Qlosi is the person that really doesn’t want glasses but is struggling. You give them Qlosi and they say, now I’m back to the way I was five, ten years ago. They’re good to go.”

Strong candidates include1:

Adults 40–65 with symptomatic presbyopia unwilling to wear readers full time
LASIK or PRK patients who don’t want to lose the freedom from glasses they invested in
Contact lens wearers frustrated with multifocal optics
Active patients whose lifestyle makes readers impractical
Pseudophakes seeking supplemental near vision support
Dr. Kevin Gee
Whether a patient wants or needs something, Qlosi gives them an opportunity to have that freedom without reaching for a pair of glasses. Whether or not they use it all the time, it gives them the relief of not feeling like they’ll be in glasses for everything they need to see up close.”

The Clear Start Kit

Recommend the Clear Start Kit for all new
Qlosi patients to establish neuroadaptation
and to set up long-term adherence
THE CLEAR START WEEK: two doses in each eye daily for 7 days1
Doses spaced 2–3 hours apart1,2
After Clear Start Week, patients can use 1 or 2 doses daily based on their needs1
The Qlosi Clear Start Kit

BlinkRx Pharmacy

Available exclusively through BlinkRx specialty pharmacy
Patients receive automated refill reminders by text or call
Free delivery to their door in 5–7 days
Introductory offer when patients get more!
30-vial supply $79; 60-vial supply $158 crossed out, $99 recommended as first order; $119 per month after first fill

30-vial supply:

$79

60-vial supply:

$158 $99

recommended as first order

$119 per month after first fill

Learn more about BlinkRx

Samples & Starter Kits

Order Patient Starter Kits to support first prescriptions
and in-office conversations about Qlosi.
Qlosi carton and vial

Not actual size

The Qlo Down

The Qlo Down is content featuring real ECPs, like you.

They’re talking about experiences with Qlosi: busting myths, chatting about patients it’s helped most, and sharing successes they’ve seen firsthand.

Real talk, real results. This is The Qlo Down
Qlosi packaging Watch more

See the struggle,
spark the solution

One conversation, one drop. Qlosi.
Qlosi carton and vial

Indication and Usage

Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

Important Safety Information

Contraindications

Hypersensitivity

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

Qlosi is not recommended to be used when iritis is present.

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the instillation of Qlosi and wait 10 minutes before reinsertion.

Avoid touching the tip of the vial to the eye or any other surface.

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

Please see full Prescribing Information here: qlosiecp.com/prescribing-information

References

  1. Qlosi [package insert]. Ponte Vedra, FL. Orasis Pharmaceuticals.
  2. Holland E, Karpecki P, Fingeret M, et al. Efficacy and safety of CSF-1 (0.4% pilocarpine hydrochloride) in presbyopia: pooled results of the NEAR phase 3 randomized, clinical trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005